Physician profile
Hang Jiang
NPI 1780136515
$2,262.95
in general payments reported to CMS, 2019-2025
10 companies · $761 in 2025
The $761 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $143 · 2021: $285 · 2022: $11.98 · 2023: $290 · 2024: $514 · 2025: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,565.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $794.02 | 2020-2025 | Total30, Precision 1, Dailies Total1 |
| Coopervision INC. | $304.60 | 2021-2025 | Clariti Contact Lens, Myday Contact Lens |
| Bausch & Lomb Americas INC. | $276.15 | 2022-2024 | Infuse, Xiidra, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $240.08 | 2019-2021 | |
| Glaukos Corporation | $149.98 | 2025 | Photrexa Viscous and Photrexa |
| Johnson & Johnson Vision Care, INC. | $147.38 | 2024-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $143.16 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $109.50 | 2025 | Xdemvy |
| Biotissue Holdings INC. | $72.89 | 2024 | |
| Abb Con-Cise Optical Group LLC | $25.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hang Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.